ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
scPharmaceuticals Inc

scPharmaceuticals Inc (SCPH)

5.01
0.17
( 3.51% )
Updated: 12:21:15

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
5.01
Bid
5.01
Ask
5.02
Volume
94,084
4.72 Day's Range 5.055
3.24 52 Week Range 8.55
Market Cap
Previous Close
4.84
Open
4.80
Last Trade
10
@
5.015
Last Trade Time
12:21:36
Financial Volume
$ 463,127
VWAP
4.9225
Average Volume (3m)
231,847
Shares Outstanding
36,054,409
Dividend Yield
-
PE Ratio
-3.30
Earnings Per Share (EPS)
-1.52
Revenue
13.59M
Net Profit
-54.81M

About scPharmaceuticals Inc

scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's lead product is Furoscix. Furoscix consist... scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's lead product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
scPharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SCPH. The last closing price for scPharmaceuticals was $4.84. Over the last year, scPharmaceuticals shares have traded in a share price range of $ 3.24 to $ 8.55.

scPharmaceuticals currently has 36,054,409 shares outstanding. The market capitalization of scPharmaceuticals is $174.50 million. scPharmaceuticals has a price to earnings ratio (PE ratio) of -3.30.

SCPH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.245.031446540884.775.294.331195384.71041851CS
40.6314.38356164384.385.2941653854.56301642CS
120.377.974137931034.645.293.242318474.23929164CS
26-0.25-4.752851711035.266.543.242244884.77746386CS
52-3.07-37.9950495058.088.553.242614885.60652297CS
156-1.04-17.19008264466.0512.753.242383896.85366775CS
260-0.29-5.471698113215.312.753.241799956.8634323CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.87
(74.77%)
146.51M
SLRXSalarius Pharmaceuticals Inc
$ 3.453
(61.36%)
23.62M
PBMPsyence Biomedical Ltd
$ 0.5841
(49.23%)
72.63M
MIRAMIRA Pharmaceuticals Inc
$ 3.351
(41.99%)
39.25M
VKTXViking Therapeutics Inc
$ 67.905
(34.71%)
12.76M
TWOU2U Inc
$ 1.5901
(-61.41%)
4.11M
KDLYKindly MD Inc
$ 1.99
(-38.20%)
614.63k
CTNTCheetah Net Supply Chain Service Inc
$ 0.30
(-37.76%)
7.6M
EZFLEzFill Holdings Inc
$ 3.9799
(-36.07%)
118.12k
MXLMaxLinear Inc
$ 15.37
(-31.05%)
3.2M
NVDANVIDIA Corporation
$ 114.955
(0.62%)
274.9M
SQQQProShares UltraPro Short QQQ
$ 8.95
(-1.21%)
153.08M
SLNASelina Hospitality PLC
$ 0.04
(-12.47%)
137.91M
POAIPredictive Oncology Inc
$ 1.87
(74.77%)
134.99M
PBMPsyence Biomedical Ltd
$ 0.5841
(49.23%)
67.12M

SCPH Discussion

View Posts
FooBarAndGrill FooBarAndGrill 2 months ago
What a freaking dud. $SCPH
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 4 months ago
March 13, 2024 - 10K
2023 Product revenues, net $13,593,000
Net loss 2022 $36,838,000 /// 2023 $54,810,000
Net loss per share, basic and diluted 2022 $1.30 /// 2023 $1.42
https://www.sec.gov/ix?doc=/Archives/edgar/data/1604950/000095017024030780/scph-20231231.htm
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 7 months ago
FUROSCIX® Revenue

Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4

Inventory levels at the end of Q4 2023 consistent with the end of Q3 2023

Unaudited cash, cash equivalents and short-term investments of approximately $76 million as of December 31, 2023
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 8 months ago
Ba-Donka-Donk
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 9 months ago
Third Quarter 2023 Financial Results and Financial Guidance

Product revenues were $3.8 million, and cost of product revenues were $1.1 million for the third quarter of 2023.

Research and development expenses were $3.4 million for the third quarter of 2023, compared to $3.7 million for the third quarter of 2022. The decrease in research and development expenses for the quarter ended September 30, 2023 was primarily due to a decrease in employee related costs and clinical study and medical affairs costs. The decrease was partially offset by an increase in device and pharmaceutical development costs.

Selling, general and administrative expenses were $14.1 million for the third quarter of 2023, compared to $6.3 million for the third quarter of 2022. The increase in selling, general and administrative expenses for the quarter ended September 30, 2023 was primarily due to an increase in employee related costs and commercial costs.

scPharmaceuticals reported a net loss of $15.6 million for the third quarter of 2023, compared to $10.2 million for the third quarter of 2022.

scPharmaceuticals ended the third quarter of 2023 with $90.2 million in cash, cash equivalents and short-term investments, compared to $118.4 million as of December 31, 2022.

As of September 30, 2023, scPharmaceuticalsโ€™ total shares outstanding was 35,859,045.

Full PR Here
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 11 months ago
$SCPH is literally asleep at the wheel. Did anyone attend the conference call?
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
Medicaid coverage of FUROSCIX effective July 1, 2023.
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
$SCPH Institutional Ownership 87.19%
https://www.nasdaq.com/market-activity/stocks/scph/institutional-holdings
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
In addition, we were also recently informed that weโ€™ll obtain national Medicaid coverage of FUROSCIX effective July 1, 2023. https://seekingalpha.com/article/4602856-scpharmaceuticals-inc-scph-q1-2023-earnings-call-transcript
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
10-Q + Webcast Wed 4:30pm ET. This will include sales from go-to-market FEB 20 thru MAR 31.
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announce-first-quarter-2023-financial-results
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
scPharmaceuticals Inc. discloses that it has two deposit accounts at Silicon Valley Bank, each with a balance of equal to or less than $250,000 as of March 10, 2023.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1604950/000119312523067253/d483112d8k.htm
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
$SCPH PR:
https://www.globenewswire.com/news-release/2023/02/21/2612086/0/en/scPharmaceuticals-Announces-Launch-and-Commercial-Availability-of-FUROSCIX-furosemide-injection.html
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
Monday 20th is Go-To-Market.
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 1 year ago
SCPH provides business updates.
https://www.globenewswire.com/news-release/2023/01/30/2597485/0/en/scPharmaceuticals-Provides-FUROSCIX-furosemide-injection-Commercial-Update.html
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
Will $SCPH ever sell a single dose of this FDA approved drug? This is the Twilight Zone.
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
The go-to-market for the Furoscix infusor/drug combo is a large undertaking. It involves building out production for both the infusor and drug. Quality control is the name of the game.
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
Furoscix administered via the Furoscix Infusor.

In addition to the Ph-Neutral formulation of Furoscix, FDA has approved the use of an automatic infusor for administration of the prescribed dosage.

Furoscix enables subcutaneous administration at home by the patient or a caregiver with the use of the On-Body Infusor, which was developed using West Pharmaceutical Services SmartDose technology. Once the pre-filled cartridge is inserted into the pre-programmed infusor and attached to the abdomen, the device is activated to deliver the 80-mg dose over five hours.

https://clinicaltrials.gov/ct2/show/NCT03458325
https://www.empr.com/home/news/fda-approves-wearable-furosemide-delivery-system-furoscix-for-outpatient-use/
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
$SCPH Prescription Drug product FUROSCIX has been added to United Healthcare's Pharmacy Benefit Programs Drug List.
https://www.uhcprovider.com/content/dam/provider/docs/public/resources/pharmacy/Drugs-with-Clinical-Programs-Commercial.pdf
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
$SCPH Prescription Drug product FUROSCIX has been added to Humana's List of covered drugs.
https://docushare-web.apps.external.pioneer.humana.com/Marketing/docushare-app?file=4473924
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
PDUFA! Approval!
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announces-fda-approval-furoscixr-furosemide
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
PDUFA! Approval!
https://scpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/scpharmaceuticals-announces-fda-approval-furoscixr-furosemide
๐Ÿ‘๏ธ0
FooBarAndGrill FooBarAndGrill 2 years ago
PDUFA After Market today?
๐Ÿ‘๏ธ0
akamaii akamaii 5 years ago
Whatโ€™s up here today
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock